Sage Journals: Discover world-class research

Abstract

Get full access to this article

View all access options for this article.

References

Gary

, Harrison

. Analysis of severe adverse events related to the use of mifepristone as an abortifacient. Ann Pharmacother 2006;40:191–7. Epub 27 Dec 2005. DOI 10.1345/aph.1G481

Napke

A commitment to pharmacovigilance: 40 years on. Uppsala Reports 2004;25:12–3.

Greene

. Fatal infections associated with mifepristone-induced abortion. N Engl J Med 2005;353:2317–8.

Spitz

, Bardin

, Benton

, Robbins

Early pregnancy termination with mifepristone and misoprostol in the United States. N Engl J Med 1998;338:1241–7.

Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: a randomized trial. World Health Organisation Task Force on Post-ovulatory Methods of Fertility Regulations. BJOG 2000;107:524–30.

Tcacencu

Mifepristone (RU-486) impairs post-surgical wound healing of the larynx. Med Sci Monit 2002;8:BR397–400.

Comment: Analysis of Severe Adverse Events Related to the Use of Mifepristone as an Abortifacient

Abstract

Get full access to this article

References